Stereotaxis ( (STXS) ) has released its Q3 earnings. Here is a breakdown of the information Stereotaxis presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Stereotaxis, a leader in surgical robotics for minimally invasive endovascular interventions, continues to advance its innovative technology portfolio, aiming to enhance patient care and operating room efficiency. In its third-quarter earnings report for 2025, Stereotaxis highlighted significant commercial progress, including the sale of two Genesis robotic systems to European hospitals and the successful launch of new products like MAGiC Sweep, which generated over $300,000 in revenue shortly after FDA clearance. The company reported total revenue of $7.5 million, with a gross margin of 55%, and noted a decrease in adjusted operating expenses compared to the previous year. Despite an operating loss of $6.6 million, Stereotaxis maintains a strong cash position with $10.5 million in cash and no debt. Looking ahead, Stereotaxis anticipates fourth-quarter revenue to exceed $9 million, driven by continued growth in both system and recurring revenue, supporting its goal of achieving over 20% annual revenue growth for 2025.